Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor The review by Corey1 and the accompanying editorial paint a very positive picture about the potential of antisense oligonucleotides (ASOs) to treat neurological diseases such as Friedrich ataxia,2 spinal muscular atrophy,3 and Duchenne muscular dystrophy. Although the principle on which ASO-based treatment is based is promising, a review of the literature, however, reveals critical lacunae in the data that have been used to claim efficacy.
Bhagavati S. Doubts About Therapy for Neurological Diseases With Antisense Oligonucleotides. JAMA Neurol. 2016;73(12):1502. doi:10.1001/jamaneurol.2016.4332
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: